Back

Shortened versus standard duration of dual antiplatelet treatment after percutaneous coronary intervention in patients with and without chronic kidney disease: a systematic review and meta-analysis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiovascular pharmacotherapy: new insights Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Anastasios Apostolos

Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, London (United Kingdom of Great Britain & Northern Ireland)

2 More presentations in this session

Presentation thumbnail
Glutathione s-transferase pi is a marker of loop diuretic resistance in patients with congestive heart failure exacerbation
Mr T. Imiela (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
The impact of body mass on cardiovascular outcomes in patients with acute coronary syndrome
Mr W. van den Broek (Nieuwegein, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular pharmacotherapy: new insights

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Sex-related outcomes in patients receiving shortened or longer dual antiplatelet treatment after percutaneous coronary intervention: a systematic review and meta-analysis.
thumbnail
Congress Presentation
A shorter duration of dual-antiplatelet therapy for percutaneous coronary intervention following acute coronary syndrome: a meta-analysis of randomized clinical trials
thumbnail
Congress Presentation
Dual antiplatelet therapy de-escalation followed by aspirin or P2Y12 inhibitor monotherapy after PCI for acute coronary syndrome: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources